| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.3109/10673229609017192 |
| P698 | PubMed publication ID | 9384954 |
| P2093 | author name string | Coyle JT | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 241-253 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Harvard Review of Psychiatry | Q5676543 |
| P1476 | title | The glutamatergic dysfunction hypothesis for schizophrenia | |
| P478 | volume | 3 |
| Q90141173 | A Natural Product with High Affinity to Sigma and 5-HT7 Receptors as Novel Therapeutic Drug for Negative and Cognitive Symptoms of Schizophrenia |
| Q24657918 | A decrease of reelin expression as a putative vulnerability factor in schizophrenia |
| Q47161237 | A magnetic resonance spectroscopy study of the anterior cingulate cortex in youth with emotional dysregulation. |
| Q48887866 | A novel mutation in the aristaless domain of the ARX gene leads to Ohtahara syndrome, global developmental delay, and ambiguous genitalia in males and neuropsychiatric disorders in females. |
| Q28263502 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia |
| Q24657354 | A review of MRI findings in schizophrenia |
| Q38122300 | A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo |
| Q34312283 | AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia |
| Q38568415 | Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia |
| Q37129963 | Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia |
| Q48273349 | Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. |
| Q44822535 | Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder |
| Q48728126 | Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. |
| Q44068198 | Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors |
| Q36247426 | Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex |
| Q44645833 | Adenosine A1 Receptor Agonists Block the Neuropathological Changes in Rat Retrosplenial Cortex after Administration of the NMDA Receptor Antagonist Dizocilpine |
| Q37103350 | Afferent drive of medial prefrontal cortex by hippocampus and amygdala is altered in MAM-treated rats: evidence for interneuron dysfunction |
| Q35034774 | Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: a postmortem study on the amygdala |
| Q30476609 | Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines |
| Q41995548 | Alteration in the plasma concentration of a DAAO inhibitor, 3-methylpyrazole-5-carboxylic acid, in the ketamine-treated rats and the influence on the pharmacokinetics of plasma D-tryptophan |
| Q38661176 | Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. |
| Q44148970 | Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function |
| Q34738418 | Altered center-surround motion inhibition in schizophrenia |
| Q30409979 | Altered serine/threonine kinase activity in schizophrenia |
| Q28590145 | Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction |
| Q31912055 | Amygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia |
| Q77343245 | An integrated view of pathophysiological models of schizophrenia |
| Q42462887 | Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure |
| Q49870570 | Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. |
| Q24674909 | Animal models of schizophrenia: a critical review |
| Q34383654 | Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia |
| Q30386608 | Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection |
| Q30479307 | Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia |
| Q38318294 | Association analysis of the GRM8 gene with schizophrenia in the Uygur Chinese population |
| Q34126455 | Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia |
| Q35600223 | Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse |
| Q44386344 | Behavioral analysis of the consequences of chronic blockade of NMDA-type glutamate receptors in the early postnatal period in rats |
| Q48225264 | Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine |
| Q41729841 | Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex |
| Q28505790 | Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors |
| Q34470675 | Brain rhythms connect impaired inhibition to altered cognition in schizophrenia |
| Q34378802 | Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework |
| Q33819365 | Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. |
| Q38035216 | Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans |
| Q44551774 | Chronic neonatal N-methyl-D-aspartate receptor blockade induces learning deficits and transient hypoactivity in young rats |
| Q33866125 | Classics in Chemical Neuroscience: Aripiprazole. |
| Q74097691 | Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics |
| Q58164139 | Cognitive coordination and its neurobiological bases: A new continent to explore |
| Q33179619 | Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects |
| Q33744368 | Comparative pharmacology of bipolar disorder and schizophrenia |
| Q51436028 | Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. |
| Q48290612 | Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice |
| Q36834289 | Conventional and atypical antipsychotics in the elderly : a review. |
| Q22241679 | Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia |
| Q37173934 | Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia |
| Q73265133 | Cortically driven Fos induction in the striatum is amplified by local dopamine D2-class receptor blockade |
| Q33811831 | Corticosteroid and neurosteroid dysregulation in an animal model of autism, BTBR mice |
| Q33845745 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia |
| Q34068005 | D-serine added to antipsychotics for the treatment of schizophrenia |
| Q36785486 | D-serine as a gliotransmitter and its roles in brain development and disease |
| Q48215054 | D2 dopamine receptor but not AMPA and kainate glutamate receptor genes show altered expression in response to long term treatment with trans- and cis-flupenthixol in the rat brain |
| Q53396523 | DAOA variants and schizophrenia: influence on diagnosis and treatment outcomes. |
| Q50023644 | Defects in Bioenergetic Coupling in Schizophrenia. |
| Q33813139 | Development, disease and degeneration in schizophrenia: a unitary pathophysiological model |
| Q36948546 | Differential activation patterns of occipital and prefrontal cortices during motion processing: evidence from normal and schizophrenic brains |
| Q46130769 | Differential effects of MK-801 on cerebrocortical neuronal injury in C57BL/6J, NSA, and ICR mice |
| Q44189362 | Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration |
| Q30592331 | Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review |
| Q30386868 | Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function |
| Q95282238 | Disordered directional brain network interactions during learning dynamics in schizophrenia revealed by multivariate autoregressive models |
| Q38751249 | Diverse roles for ionotropic glutamate receptors on inhibitory interneurons in developing and adult brain |
| Q73593161 | Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment |
| Q33541919 | Do hallucinogens cause residual neuropsychological toxicity? |
| Q45248983 | Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists |
| Q24631189 | Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes |
| Q45972449 | Duration of untreated illness (DUI) and schizophrenia sub-types: a collaborative study between the universities of Milan and Moscow. |
| Q64095132 | Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress |
| Q43807384 | Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex |
| Q73901658 | Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine |
| Q48362755 | Effects of antipsychotics, vitamin E, and MK-801 on dopamine dynamics in the rat brain following discontinuation of cocaine |
| Q44221553 | Effects of cocaine and reserpine administration on RNA editing of rat 5-HT2C receptor estimated by primer extension combined with denaturing high-performance liquid chromatography. |
| Q35089938 | Effects of estrogen on brain development and neuroprotection--implications for negative symptoms in schizophrenia |
| Q37662441 | Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials |
| Q51009647 | Effects of low-dose D-serine on recognition and working memory in mice. |
| Q37438631 | Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia |
| Q48345910 | Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. |
| Q30458051 | Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. |
| Q90728999 | Electoretinographic evidence of retinal ganglion cell-dependent function in schizophrenia |
| Q30362188 | Electrophysiological Endophenotypes for Schizophrenia |
| Q78228755 | Electrophysiological effects of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons |
| Q35115613 | Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia |
| Q37438984 | Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development |
| Q35603175 | Extracellular matrix abnormalities in schizophrenia |
| Q34398564 | Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia |
| Q73794746 | Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats |
| Q44793030 | Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release |
| Q46170742 | Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments |
| Q24597790 | GABAergic interneuron origin of schizophrenia pathophysiology. |
| Q34661613 | Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine |
| Q36990973 | Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities |
| Q48496355 | Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug t |
| Q34338239 | Genetic animal models: focus on schizophrenia |
| Q36925317 | Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. |
| Q30478274 | Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia |
| Q34415862 | Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study |
| Q55312811 | Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia. |
| Q36756365 | Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions |
| Q35847653 | Glutamate as a therapeutic target in psychiatric disorders |
| Q41673368 | Glutamate in schizophrenia: clinical and research implications |
| Q34330678 | Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. |
| Q38151703 | Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments |
| Q34590422 | Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders? |
| Q33891806 | Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia |
| Q24555193 | Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter |
| Q30477522 | Glycine transport inhibitors for the treatment of schizophrenia |
| Q41181860 | Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway |
| Q28275290 | Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia |
| Q48411622 | Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. |
| Q47734973 | Hippocampal GABAergic Inhibitory Interneurons |
| Q73815830 | Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies |
| Q36053292 | Hippocampal temporal-parietal junction interaction in the production of psychotic symptoms: a framework for understanding the schizophrenic syndrome |
| Q30699614 | Human metabotropic glutamate receptor 2 gene (GRM2): chromosomal sublocalization (3p21.1-p21.2) and genomic organization |
| Q30489750 | Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling |
| Q35167939 | Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study |
| Q37944127 | Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? |
| Q28078158 | Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy |
| Q37320771 | Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. |
| Q26769948 | In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders |
| Q48264745 | In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia |
| Q37420164 | Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study |
| Q48284591 | Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia |
| Q30468818 | Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes |
| Q46516683 | Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker |
| Q36447192 | Influence of Genetic Variants of the N-Methyl-D-Aspartate Receptor on Emotion and Social Behavior in Adolescents |
| Q35892576 | Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia |
| Q33575236 | Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting |
| Q73816105 | Inhibition of striatal dopamine release by glycine and glycyldodecylamide |
| Q40531131 | Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action |
| Q44247358 | Interaction of stress and strain on glutamatergic neurotransmission: relevance to schizophrenia |
| Q35844158 | Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice |
| Q38376655 | Is duration of illness really influencing outcome in major psychoses? |
| Q59355241 | Is the History of Substance Abuse Correlated with Neuropsychiatric Disorders and Co-morbid HIV Infection? An Urban Population Study |
| Q48126400 | Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man. |
| Q34152191 | LY404187: a novel positive allosteric modulator of AMPA receptors |
| Q34415609 | LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. |
| Q35592555 | Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation |
| Q38709794 | MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia |
| Q24671667 | Magnocellular contributions to impaired motion processing in schizophrenia |
| Q38527208 | Major diencephalic inputs to the hippocampus: supramammillary nucleus and nucleus reuniens. Circuitry and function |
| Q33932502 | Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia |
| Q37463647 | Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy |
| Q34113742 | Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population |
| Q28510751 | Mice with reduced NMDA receptor expression display behaviors related to schizophrenia |
| Q24644849 | MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction |
| Q28382954 | MicroRNAs in Neurotoxicity |
| Q34574117 | Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. |
| Q44563712 | Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent |
| Q45249011 | Modulation of striatal dopamine release by glycine transport inhibitors |
| Q30428213 | Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment |
| Q37298159 | N-Methyl D-Aspartate Receptor Antagonist Kynurenic Acid Affects Human Cortical Development. |
| Q28285432 | N-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder |
| Q37981289 | NAAG, NMDA receptor and psychosis |
| Q42192369 | NMDA receptor and schizophrenia: a brief history |
| Q28205016 | NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development |
| Q38578480 | NMDA receptor function, memory, and brain aging |
| Q34197064 | NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons |
| Q36042941 | NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus |
| Q24644168 | Neural synchrony in schizophrenia: from networks to new treatments |
| Q28743857 | Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders |
| Q30698640 | Neuroanatomy and neurophysiology in schizophrenia |
| Q35042195 | Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory |
| Q30403302 | Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate |
| Q37148229 | Neuroscience and psychopharmacology into the next millennium. |
| Q35236252 | Neurotoxicity of NMDA antagonists: a glutamatergic theory of schizophrenia based on selective impairment of local inhibitory feedback circuits. |
| Q41656936 | Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia |
| Q64062621 | Oligodendrocytes: Potential of Discovering New Treatment Targets |
| Q28588903 | Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder. |
| Q36409596 | Overview of Glutamatergic Dysregulation in Central Pathologies |
| Q34494844 | Oxidative stress in schizophrenia: an integrated approach |
| Q34274859 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents |
| Q46958764 | Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. |
| Q60439965 | Phenomenology, context, and self-experience in schizophrenia |
| Q24602550 | Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex |
| Q42027942 | Possible role for interactions between 5-lipoxygenase (5-LOX) and AMPA GluR1 receptors in depression and in antidepressant therapy |
| Q89983282 | Post-translational protein modifications in schizophrenia |
| Q33556077 | Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes |
| Q38958804 | Potential synergistic action of 19 schizophrenia risk genes in the thalamus. |
| Q64060513 | Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia |
| Q44672168 | Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. |
| Q73405627 | Presence of NMDA-type glutamate receptors in cingulate corticostriatal terminals and their postsynaptic targets |
| Q88012630 | Presynaptic Effects of N-Methyl-D-Aspartate Receptors Enhance Parvalbumin Cell-Mediated Inhibition of Pyramidal Cells in Mouse Prefrontal Cortex |
| Q30480517 | Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia |
| Q33983993 | Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study |
| Q33754399 | Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia |
| Q36852122 | Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex |
| Q38903697 | Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia |
| Q36310867 | Psychosocial disabilities in patients with schizophrenia |
| Q64970477 | Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity. |
| Q37979291 | Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia |
| Q37610236 | Recent advances in the pharmacotherapy of autism |
| Q30453229 | Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia |
| Q44407146 | Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine |
| Q34235427 | Reinforcement ambiguity and novelty do not account for transitive inference deficits in schizophrenia |
| Q28239852 | Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families |
| Q44618474 | Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists |
| Q24523918 | Review of the use of Topiramate for treatment of psychiatric disorders |
| Q34561031 | SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. |
| Q36756401 | Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder |
| Q34268457 | Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. |
| Q38765239 | Schizophrenia: genetics, prevention and rehabilitation |
| Q35760205 | Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator |
| Q28577907 | Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation |
| Q28343888 | Semantic disturbance in schizophrenia and its relationship to the cognitive neuroscience of attention |
| Q34546952 | Semantics and N400: insights for schizophrenia |
| Q46459393 | Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition |
| Q41810408 | Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology |
| Q50054332 | Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). |
| Q103011053 | Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study) |
| Q35144764 | Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission |
| Q37131036 | Spatial characteristics of white matter abnormalities in schizophrenia |
| Q30417394 | Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. |
| Q36246819 | Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia |
| Q33760635 | Symptom provocation studies in psychiatric disorders: scientific value, risks, and future |
| Q91816977 | Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology |
| Q52173663 | Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. |
| Q60037831 | Synchronous dynamics for cognitive coordination: But how? |
| Q48561060 | Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents. |
| Q37137008 | Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem |
| Q60536516 | Targeting glutamate to treat schizophrenia: lessons from recent clinical studies |
| Q38223276 | Targeting of NMDA receptors in new treatments for schizophrenia |
| Q50138246 | The Role of Serine Racemase in the Pathophysiology of Brain Disorders. |
| Q93359680 | The Stanley Neuropathology Consortium Integrative Database (SNCID) for Psychiatric Disorders |
| Q38056122 | The biochemical womb of schizophrenia: A review |
| Q48651690 | The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia. |
| Q35019122 | The effects of early and sustained intervention on the long-term morbidity of schizophrenia |
| Q35186635 | The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies |
| Q33578312 | The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice |
| Q34363257 | The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders |
| Q40190681 | The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats |
| Q73553209 | The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies |
| Q41885537 | The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers |
| Q47989124 | Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice |
| Q30981438 | Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. |
| Q33845809 | Topiramate antagonizes MK-801 in an animal model of schizophrenia |
| Q50677578 | Tract-based magnetic resonance spectroscopy of the cingulum bundles at 7 T. |
| Q35739457 | Translating glutamate: from pathophysiology to treatment |
| Q36831867 | Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia |
| Q34338202 | Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs |
| Q41945244 | Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction. |
| Q42949861 | Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics |
| Q59782767 | Why do schizophrenic patients hallucinate? |
| Q34003528 | Why is D-serine nephrotoxic and alpha-aminoisobutyric acid protective? |
| Q24294371 | d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia |
| Q51730519 | d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner. |
Search more.